Patient safety and healthcare quality of U.S. laboratory developed tests (LDTs) in the AI/ML era of precision medicine.

导出 LinkOut

翻译打印收藏纠错

作者： Emma L,Kurnat-Thoma ^[1]

作者单位： Georgetown Institute for Women, Peace and Security, Walsh School of Foreign Service, Georgetown University, Washington, DC, United States.;Precision Policy Solutions, LLC, Bethesda, MD, United States. ^[1]

关键词 CMS clinical laboratory improvement amendments (CLIA)FDA proposed rule genomic tests health care quality laboratory developed tests (LDTs)patient safety regulatory compliance return of results (RoR)

DOI 10.3389/fmolb.2024.1407513

PMID 39165642

发布时间 2024-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in molecular biosciences

2024年11卷

1407513页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Patient safety and healthcare quality of U.S. laboratory developed tests (LDTs) in the AI/ML era of precision medicine.

Frontiers in molecular biosciences

相似文献

Frontiers in molecular biosciences

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patient safety and healthcare quality of U.S. laboratory developed tests (LDTs) in the AI/ML era of precision medicine.

Frontiers in molecular biosciences

相似文献

Frontiers in molecular biosciences

相关期刊

检索历史清除